Prescribing information

 

The majority (approximately 85%) of relapsing-remitting multiple sclerosis (RRMS) patients will eventually progress to secondary progressive multiple sclerosis (SPMS).1 Despite this, SPMS diagnosis continues to be challenging in clinical practice2 and is typically diagnosed retrospectively in the clinic by a history of gradual worsening after an initial relapsing disease course, with or without acute exacerbations during the progressive course.3 Prior to the introduction of MAYZENT, treatment options were limited for SPMS patients with active disease. MAYZENT is the first and only oral treatment recommended by the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC)* for adults living with SPMS with active disease.4,5

This case study tool is designed to help healthcare professionals recognise the early signs of progression and to subsequently identify SPMS patients with active disease, who may benefit from treatment with MAYZENT. MAYZENT is indicated for the treatment of adult patients with SPMS with active disease evidenced by relapses or imaging features of inflammatory activity.

There are three different case studies to explore that are based upon real-life SPMS patients with active disease based in the United States. Dr Emma Tallantyre, clinical senior lecturer at Cardiff University, also provides her expert opinion on each case and discusses how she would diagnose and manage these patients in the clinic. Watch Dr Tallantyre introduce the case study tool below.

 

Explore the three patient case studies below and watch Dr Tallantyre’s assessment of each case

Images and names are not the actual patients.

Thumbnail image of hypothetical patient Heather, a 54-year-old woman previously diagnosed with RRMS with worsening cognitive symptoms and spasticity who has experienced a recent relapse.

Heather

A 54-year-old woman previously diagnosed with RRMS with worsening cognitive symptoms and spasticity who has experienced a recent relapse.

Thumbnail image of hypothetical patient Fatima, a 49-year-old woman previously diagnosed with RRMS who is concerned about worsening balance and neuropathic pain.

Fatima

A 49-year-old woman previously diagnosed with RRMS who is concerned about worsening balance and neuropathic pain.

Thumbnail image of hypothetical patient James, a 42-year-old man previously diagnosed with RRMS who has noticed a decline in his gait and worsening balance despite a lack of relapses.

James

A 42-year-old man previously diagnosed with RRMS who has noticed a decline in his gait and worsening balance despite a lack of relapses.

 

Indication: Mayzent is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.

MAYZENT is not licensed for RRMS. Case studies are adapted from real patient cases in the United States. This promotional tool was developed and funded by Novartis Pharmaceuticals UK Ltd.

*Full SMC advice for reference ADVICE: following a full submission siponimod (Mayzent®) is accepted for use within NHS Scotland. Indication under review: treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity. In a randomised, double-blind, placebo-controlled phase III study, siponimod was associated with a reduction in disability progression confirmed after 3 months in patients with SPMS. This advice applies only in the context of an approved NHS Scotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.

MS, multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis.

References

  1. Khurana V, Medin J. Poster presented at the 7th Joint ECTRIM-ACTRIMS Meeting; 25–28 October 2017; Paris, France;
  2. Bogosian A et al. BMJ Open. 2019;9:e026421;
  3. Lublin FD et al. Neurology. 2014;83(3):278–286;
  4. NICE. Siponimod for treating secondary progressive multiple sclerosis. https://www.nice.org.uk/guidance/ta656/resources/siponimod-for-treating-... [Accessed January 2022].
  5. SMC. Siponimod 250 microgram and 2mg film-coated tablets (Mayzent®). https://www.scottishmedicines.org.uk/media/5468/siponimod-mayzent-final-... [Accessed January 2022].
  6. MAYZENT (siponimod) Summary of Product Characteristics.
Rate this content: 
Average: 4.7 (3 votes)
UK | January 2022 | 164592
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]